Skip to main content

Table 3 BBACL cohort patient demographics

From: Alzheimer’s disease-specific transcriptomic and epigenomic changes in the tryptophan catabolic pathway

 

SCD

MCI

Dementia

MCI-D

MCI-MCI

Demographics variables

N

39

168

55

80

88

Age at baseline

59.62 ± 9.50

72.65 ± 7.69

74.44 ± 7.89

74.94 ± 6.24

70.57 ± 8.30

Gender (male/female)

33/6

89/79

24/31

45/35

44/44

Education

(low/middle/high)

13/16/10

64/66/38

27/20/8

26/31/23

38/35/15

Lifestyle variables

BMI (kg/m2)

25.95 ± 4.00

(n = 22)

26.66 ± 4.17

(n = 121)

24.67 ± 3.97

(n = 42)

26.28 ± 3.67

(n = 58)

27.01 ± 4.57

(n = 63)

Smoking status

(never/< 6 months/

> 6 months/current)

17/0/13/8

74/1/61/22

30/0/17/4

38/0/32/7

36/1/29/15

Alcohol consumption

(yes/no)

30/6

116/42

38/12

60/17

56/25

Cognitive test

 MMSE

28.31 ± 1.58

26.65 ± 2.30

24.07 ± 2.28

26.03 ± 2.42

27.23 ± 2.04

 normMMSE

80.52 ± 14.04

68.41 ± 15.63

53.26 ± 11.03

64.38 ± 15.30

72.07 ± 15.10

Pyrosequencing (%)

     

 IDO2 (cg11251498)

64.96 ± 4.55

63.31 ± 5.12

63.91 ± 6.06

63.39 ± 5.93

63.23 ± 4.28

  1. Overview of patient characteristics in the BBACL cohort used in this study. Data are presented in n or mean ± SD
  2. Abbreviations: SCD subjective cognitive decline, MCI mild cognitive impairment, MCI-D MCI to dementia converters, MCI-MCI MCI to MCI non-converters, MMSE mini mental state examination, normMMSE normalized mini mental state examination